UOC
OCUL icon

UBS O'Connor’s Ocular Therapeutix OCUL Stock Holding History

UBS O'Connor’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-210,205
Closed -$1.95M – 403
2025
Q2 		$1.95M Sell
210,205
-48,158
-19% -$377K 0.05% 162
2025
Q1 		$1.89M Sell
258,363
-12,059
-4% -$92.7K 0.04% 129
2024
Q4 		$2.31M Buy
270,422
+48,763
+22% +$476K 0.06% 141
2024
Q3 		$1.93M Sell
221,659
-17,000
-7% -$140K 0.05% 179
2024
Q2 		$1.63M Buy
238,659
+50,081
+27% +$309K 0.05% 228
2024
Q1 		$1.72M Sell
188,578
-143,513
-43% -$1.02M 0.05% 206
2023
Q4 		$1.48M Sell
332,091
-10,020
-3% -$29.6K 0.05% 218
2023
Q3 		$1.07M Buy
342,111
+40,000
+13% +$164K 0.02% 327
2023
Q2 		$1.56M Sell
302,111
-61,175
-17% -$364K 0.03% 333
2023
Q1 		$1.91M Buy
+363,286
New +$1.73M 0.05% 324
2022
Q4 		– Sell
-223,066
Closed -$926K – 223
2022
Q3 		$926K Sell
223,066
-289,820
-57% -$1.46M 0.01% 759
2022
Q2 		$2.06M Buy
+512,886
New +$1.94M 0.02% 643

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS O'Connor's OCUL Position: Q3 2025 in Review

UBS O'Connor sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 210,205 shares — an estimated $1.95M sold.

UBS O'Connor first reported a position in OCUL in Q2 2022 and held it in 12 quarters. The position peaked at $2.31M in Q4 2024. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • UBS O'Connor reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 210,205 Ocular Therapeutix shares in Q3 2025, an estimated $1.95M.
  • UBS O'Connor first reported a position in Ocular Therapeutix in Q2 2022 and held it in 12 quarters.
  • UBS O'Connor's Ocular Therapeutix position peaked at $2.31M in Q4 2024.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.